This is a preview of subscription content, log in via an institution to check access.
Notes
epidermal growth factor receptor
funded by Roche Molecular Diagnostics
References
Towse A, et al. Cost-Effectiveness of Cobas(R) Egfr Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic Nsclc: a Uk Payer Perspective. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN103, 2 Nov 2013.
Crespo C, et al. Head to Head Economic Evaluation of Two Genomic Profiles of Recurrence Risk for Breast Cancer, Mammaprint Versus Oncotype Dx, in Spain. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN139, 2 Nov 2013.
Rights and permissions
About this article
Cite this article
Genetic profiling tests show their worth for patients with cancer. PharmacoEcon Outcomes News 692, 10 (2013). https://doi.org/10.1007/s40274-013-0897-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0897-1